CAR-NK cell therapy for severe autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have one of these autoimmune diseases: lupus, systemic sclerosis, inflammatory myositis, ANCA vasculitis, Sjögren's syndrome, or antiphospholipid syndrome—and your disease is not controlled by standard treatments.
- Your blood counts, liver, kidney, and heart function are within safe ranges for this trial.
- You have not had another cancer in the last 5 years (except some skin or cervical cancers).
- You are not pregnant, breastfeeding, or planning pregnancy, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
This trial tests a new type of 'universal' CAR-T cell therapy (made from donor cells) combined with immune-suppressing drugs for people with severe autoimmune diseases that haven't responded to standard treatments. The goal is to see if this approach can control the immune system and reduce disease activity.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.